Table 1.
Basic demographics, MRI/PI-RADS characteristics, and reference standard details of the selected studies.
| Reference, Year | Data Source, n, Country | Dataset Year/s | csPCa, n (%) | PZ, n (%) | MRI Vendor, Tesla | PI-RADS lesions | Reference Standard, MRI to Procedure | Biopsy Technique |
|---|---|---|---|---|---|---|---|---|
| Dominguez et al. 2023 [24] | Single-center, 86, Chile | 2017–2021 | 66 (0.77) | 81 (0.94) | Philips, 3 | ≥3 | PB, NR | MRI/US fusion, TRUS |
| Prata et al. 2023 [25] | Single-center, 91, Italy | 2019–2020 | 39 (0.43) | NR | Siemens, 1.5 | ≥3 | PB, within 4 weeks | MRI/US fusion, TRUS |
| Jin et al. 2023 [26] | Multicenter, 463, China | 2018–2019 | 100 (0.22) | 216 (0.47) | Siemens/Philips, 3 | 3 | PB, within 4 weeks | MRI/US fusion, TRUS |
| Hamm et al. 2023 a [27] | Single-center, 1224, GER | 2012–2017 | 595 (0.49) | 1935 (0.59) b | Siemens, 3 | ≥1 | PB, within 6 months | NR |
| Hong et al. 2023 a [28] | Single-center, 171, Korea | 2018–2022 | 40 (0.37) | 81 (0.47) | Multivendor, 3 | ≥3 | RP, NR | NA |
| Jing et al. 2022 [29] | Multicenter, 389, China | 2016–2021 | 270 (0.69) | 190 (0.49) | GE/UI, 3 | ≥2 | RP, within 12 weeks | NA |
| Zhu et al. 2022 [30] | Single-center, 347, China | 2017–2020 | 235 (0.68) | 212 (0.68) c | GE, 3 | NR | PB, within 12 weeks | CT, TRUS |
| Jiang et al. 2022 a [31] | Single-center, 1230, China | 2012–2019 | 856 (0.63) b | 853 (0.63) b | Siemens/UI, 3 | ≥1 | PB, within 4 weeks | MRI/US fusion, TRUS |
| Liu et al. 2021 [32] | Single-center, 402, USA | 2010–2018 | 303 (0.75) b | 364 (0.78) b | NR, 3 | ≥3 | RP, NR | NA |
| Lim et al. 2021 [33] | Multicenter, 158, Canada | 2015–2018 | 29 (0.18) b | 79 (0.49) b | Siemens/GE, 3 | 3 | PB, NR | CT, TRUS |
| Hectors et al. 2021 [34] | Single-center, 240, USA | 2015–2020 | 28 (0.12) | NR | Siemens/GE, 3 | 3 | PB, within 12 months | MRI/US fusion, TRUS |
| Castillo et al. 2021 [35] | Multicenter, 107, NL | 2011–2014 | 112 (0.55) b | 137 (0.67) b | GE/Siemens/Philips, 3/1.5 | ≥1 | RP, NR | NA |
| Li et al. 2020 [36] | Single-center, 381, China | 2014–2017 | 142 (0.37) | NR | Philips, 3 | NR | PB, NR | TRUS |
| Zhong et al. 2019 [37] | Single-center, 140, USA | 2010–2016 | 105 (0.49) b | NR | Siemens, 3 | NR | RP, NR | NA |
csPCa = clinically significant prostate cancer, CT = cognitive targeting, GE = General Electrics, GER = Germany, MRI = magnetic resonance imaging, NA = not applicable, NL = Netherlands, NR = not reported, PB = prostate biopsy, PZ = peripheral zone, PI-RADS = Prostate Imaging Reporting and Data System, RP = radical prostatectomy, TRUS = trans-rectal ultrasound, UI = United Imaging, US = ultrasound, USA = United States of America. a Data from external validation sets are not included in the description (see reference for further details); b Data referred to as annotated lesions; c Data are for csPCa lesions.